Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BN82002 (CDC25 Phosphatase Inhibitor I) 是一种CDC25 phosphatase 家族的有效的、不可逆的、选择性的泛抑制剂。它显示出比 CD45 酪氨酸磷酸酶高约 20 倍的选择性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 361 | 现货 | ||
5 mg | ¥ 898 | 现货 | ||
10 mg | ¥ 1,230 | 现货 | ||
25 mg | ¥ 2,220 | 现货 | ||
50 mg | ¥ 3,720 | 现货 | ||
100 mg | ¥ 5,350 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 893 | 现货 |
产品描述 | BN82002 (CDC25 Phosphatase Inhibitor I) is a synthetic inhibitor of CDC25 phophatases |
靶点活性 | CDC25B2:3.9 μM, CDC25A:2.4 μM, CDC25B3:6.3 μM, CDC25C:5.4 μM, CDC25C-cat:4.6 μM |
体外活性 | The effect of BN82002 on cell proliferation is evaluated in vitro on several human tumor cell lines. Menadione is used as a control, that has been reported to inhibit cell proliferation. All of the examined cell lines are sensitive to BN82002 and Menadione in a concentration-dependent manner in the low micromolar range. The most sensitive is the pancreatic cancer cell line MIA PaCa-2 with an IC50 of 7.2 μM, and the less sensitive cell line is the colon cancer HT-29 with an IC50 of 32.6 μM. The range of activity is very similar to the one observed with menadione (5-15 μM). It is also showed that 50 μM BN82002 is a concentration that fully inhibits cell proliferation, the cell cycle distribution is only modestly affected with a slight decrease in S phase and an increase in cells containing both a G1 and a G2 DNA content, suggesting that the cells treated with BN82002 are arrested at various stages of the cell cycle. |
别名 | CDC25 Phosphatase Inhibitor I |
分子量 | 359.42 |
分子式 | C19H25N3O4 |
CAS No. | 396073-89-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 150 mg/mL (417.34 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.7823 mL | 13.9113 mL | 27.8226 mL | 69.5565 mL |
5 mM | 0.5565 mL | 2.7823 mL | 5.5645 mL | 13.9113 mL | |
10 mM | 0.2782 mL | 1.3911 mL | 2.7823 mL | 6.9557 mL | |
20 mM | 0.1391 mL | 0.6956 mL | 1.3911 mL | 3.4778 mL | |
50 mM | 0.0556 mL | 0.2782 mL | 0.5565 mL | 1.3911 mL | |
100 mM | 0.0278 mL | 0.1391 mL | 0.2782 mL | 0.6956 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BN82002 396073-89-5 Metabolism Phosphatase CDC25C CDC25A inhibit BN 82002 CDC25B3 MIA PaCa-2 Inhibitor CDC25B2 BN-82002 CDC25 Phosphatase Inhibitor I inhibitor